AI Article Synopsis

  • * The study involved 116 PsA patients, comparing the efficacy of secukinumab and adalimumab over a year with focus on ACR20 response at week 12, among other evaluations.
  • * Results showed no significant difference in ACR20 response, but secukinumab excelled in treating severe skin issues (PASI90), while adalimumab was better for ultrasound-confirmed joint inflammation.

Article Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder affecting 30% of psoriatic patients. Effective treatment, especially with biologics like IL-17 and TNF inhibitors, is vital for improving patient outcomes. This study aimed to compare the efficacy of secukinumab and adalimumab in PsA patients through clinical and ultrasonographic evaluations. We enrolled 116 PsA patients, with 58 patients receiving secukinumab and 58 receiving adalimumab. Regular follow-ups were conducted at weeks 4, 12, 24, and 52. The primary outcome was the proportion of patients achieving at least a 20% improvement in the ACR response (ACR20) at week 12, with additional evaluations for axial arthritis, enthesitis, skin involvement, minimal disease activity, health assessment questionnaire, and ultrasound changes. There was no significant difference in ACR20 response between the two groups at week 12 (OR: 0.59, 95% CI: 0.26-1.37,  = 0.22). However, secukinumab demonstrated superior efficacy in achieving Psoriasis Area and Severity Index (PASI)90 (OR: 2.25, 95%CI: 1.07-4.74,  = 0.03), while adalimumab showed better improvement in ultrasound synovitis count (β: 0.94, 95%CI: 0.09-1.79,  = 0.03) and synovitis PD signal (β: 0.20, 95%CI: 0.03-0.36,  = 0.02). In conclusion, both treatments were highly effective for PsA, with secukinumab being more suitable for severe skin involvement and adalimumab for significant ultrasound-confirmed synovitis.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2024.2411849DOI Listing

Publication Analysis

Top Keywords

ultrasound-confirmed synovitis
8
psoriatic arthritis
8
psa patients
8
skin involvement
8
secukinumab
5
patients
5
superior adalimumab
4
adalimumab versus
4
versus secukinumab
4
secukinumab ultrasound-confirmed
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!